alexa An Analysis Of The Use Of Neo-adjuvant Chemotherapy With Trastuzumab For Patients With HER-2 Positive Breast Cancer
ISSN: 2572-4118

Breast Cancer: Current Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Breast Cancer
June 15-17, 2017 London, UK

Ik Shin Chin, Canada Cherry and Racha Kussaibati
Birmingham Heartlands Hospital, UK
Posters & Accepted Abstracts: Breast Can Curr Res
DOI: 10.4172/2572-4118-C1-006
Use of anti-HER-2 therapy with chemotherapy in the neoadjuvant setting improves pathological complete response (PCR) rate. Patients with HER2-overexpressing tumors who achieve PCR had better event-free survival and overall survival. The proportion of patients achieving PCR with addition of neoadjuvant trastuzumab is 22.6-65.2%. Dual anti-HER-2 therapy has been recommended in selected high risk cases. This study primary aim is to determine PCR rate in HER-2 positive breast cancer patients who have received neoadjuvant chemotherapy and trastuzumab in the heart of England Foundation Trust, and to identify their tumor characteristics. Secondary aims are to establish proportion of patients who had breast conserving surgery and those who developed recurrence or metastases. Data was collected retrospectively to include cases from January 2011 to 2016 using the hospital electronic system. 18 patients were identified who had HER-2 positive invasive ductal carcinoma and received neoadjuvant fluorouracil, epirubicin and cyclophosphamide followed by docetacel and trastuzumab 16(89%) had a pathological response and 10(56%) had a complete pathological response. Among those who achieved PCR, 50% were hormonal receptor negative and 70% had graded 3 tumors and positive lymph nodes. Overall, 44% of patients had breast conserving surgery. One patient developed local recurrence and two patients had metastases. Our data showed that the rate of PCR achieved in our unit is comparable with other studies. Patients with more aggressive tumors appeared to achieve a better response however a larger sample size is needed to further strengthen this association.

Ik Shin Chin is a Specialty Registrar Trainee in medical oncology. She is currently working with the breast care team in the Heart of England NHS Foundation Trust in Birmingham, West Midlands.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version